MiCo BioMed Co Ltd
KOSDAQ:214610
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MiCo BioMed Co Ltd
Cash & Cash Equivalents
MiCo BioMed Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MiCo BioMed Co Ltd
KOSDAQ:214610
|
Cash & Cash Equivalents
₩13.7B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
43%
|
|
|
I
|
I Sens Inc
KOSDAQ:099190
|
Cash & Cash Equivalents
₩45B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
C
|
Classys Inc
KOSDAQ:214150
|
Cash & Cash Equivalents
₩37.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
64%
|
|
|
W
|
Won Tech Co Ltd
KOSDAQ:336570
|
Cash & Cash Equivalents
₩32.8B
|
CAGR 3-Years
445%
|
CAGR 5-Years
90%
|
CAGR 10-Years
N/A
|
|
|
V
|
Viol Co Ltd
KOSDAQ:335890
|
Cash & Cash Equivalents
₩35.1B
|
CAGR 3-Years
79%
|
CAGR 5-Years
77%
|
CAGR 10-Years
N/A
|
|
|
S
|
Seers Technology Co Ltd
KOSDAQ:458870
|
Cash & Cash Equivalents
₩10.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MiCo BioMed Co Ltd
Glance View
MiCo BioMed Co. Ltd. engages in the development, manufacture and sale of in vitro diagnosis medical devices and diagnostic reagents. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2015-06-22. The firm operates its business through three segments. The Molecular Diagnosis segment mainly manufactures and sells products such as nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. The Biochemical Diagnosis segment mainly manufactures and supplies products such as complex diagnostics, anemia meters, blood glucose meters, medical devices and strips. The Immunodiagnostic Business segment mainly produces and sells immunodiagnostic devices and immunodiagnostic kits.
See Also
What is MiCo BioMed Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
13.7B
KRW
Based on the financial report for Dec 31, 2024, MiCo BioMed Co Ltd's Cash & Cash Equivalents amounts to 13.7B KRW.
What is MiCo BioMed Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
43%
Over the last year, the Cash & Cash Equivalents growth was 46%. The average annual Cash & Cash Equivalents growth rates for MiCo BioMed Co Ltd have been -17% over the past three years , 7% over the past five years , and 43% over the past ten years .
